Tests for the quantification of human pancreatic elastase 1

Pancreatic elastase 1
Two ELISA test kits (based on monoclonal antibodies) are available for the determination of pancreatic elastase 1. The stool test quantifies E1 in stool, allowing the diagnosis or exclusion of pancreatic exocrine insufficiency, which can be caused by chronic pancreatitis, cystic fibrosis, pancreatic tumor, cholelithiasis or diabetes mellitus for example.
The serum test quantifies E1 in serum, allowing the diagnosis or exclusion of an acute pancreatitis or an inflammatory episode of chronic pancreatitis or ERCP- or gallstone-induced pancreatitis.

Stool Test

Pancreas

Human pancreatic elastase 1 (E1) remains undegraded during intestinal transit. Therefore its concentration in faeces reflects pancreatic exocrine function. The diagnostic efficiency of pancreatic elastase 1 determination in stool has been evaluated in several clinical studies. Stein et al. (1993 & 1996, 1997) and Löser et al. (1995 & 1996) compared the E1 determination with invasive intubation tests, the secretin-pancreozymin test and the secretin-caerulein test, respectively. Both authors report a sensitivity and specificity greater than 90% for the diagnosis of exocrine pancreatic insufficiency. In contrast to the fecal chymotrypsin assay, even a moderate pancreatic insufficiency can be detected by E1 determination (Löser et al., 1995 & 1996, Gullo et al., 1999).

Serum Test

Human pancreatic elastase 1 is synthesized from the acinar cells of the pancreas. During an inflammatory episode of the pancreas, E1 is released into the blood circulation. Thus the quantification of pancreatic elastase 1 in the serum allows diagnosis or exclusion of acute pancreatitis.

Click here to download our flyer.

More …

ScheBo®   Pancreatic Elastase 1™ Serum Test

pancreatic-elastase-2Diagnosis/Exclusion of Acute Pancreatitis

Main indications and diagnosis:

  • Diagnosis/Exclusion of Acute Pancreatitis
  • Diagnosis of ERCP- or gallstone-induced pancreatitis
  • Follow-up study of acute pancreatitis

Advantages

E1 is absolutely pancreas-specific. Like other pancreatic enzymes, E1 is released into the blood circulation during an inflammatory episode. Due to its longer half-life, compared to amylase and lipase, its concentration remains elevated longer, and enables detection of an acute pancreatitis even three of four days after onset of the disease. In contrast to amylase and lipase, the serum E1 concentration is only marginally increased in patients with renal insufficiency.

» The test
Further indications, advantages, reference concentration, specificity and sensitivity, method of detection, sample material, short protocol

» References/literature download
Please find here selected literature as download. The complete list of references is to be found on “References/literature fax request”.

» References/literature fax request
Here you can download a pdf-file with a list of references/literature. If you you are interested in any of these publications please fill in the form, fax it to us and we will send it to you free of charge.

ScheBo®  Pancreatic Elastase 1™ Stool Test

pancreatic-elastase-stool-testThe new gold standard for non-invasive pancreatic function testing

Abdominal Pain – Maldigestion – Malassimilation – Chronic Pancreatitis – Cystic Fibrosis – Post-traumatic injuries

Is the pancreas involved?

The reliable and cost-effective

ScheBo®  Pancreatic Elastase 1™ Stool Test gives you the answer.

The new gold standard!

The test is the new gold standard for non-invasive pancreatic function testing. It has been evaluated in comparisons with the invasive secretin-pancreozymin and secretin-caerulein tests.

Human pancreatic elastase 1 (E1) remains undegraded during intestinal transit. Therefore its concentration in faeces reflects pancreatic exocrine function. The diagnostic efficiency of pancreatic elastase 1 determination in stool has been evaluated in several clinical studies. Stein et al. (1993 & 1996, 1997) and Löser et al. (1995 & 1996) compared the E1 determination with invasive intubation tests, the secretin-pancreozymin test and the secretin-caerulein test, respectively. Both authors report a sensitivity and specificity greater than 90% for the diagnosis of exocrine pancreatic insufficiency. On contrast to the fecal chymotrypsin assay, even a moderate pancreatic insufficiency can be detected by E1 determination (Löser et al., 1995 & 1996, Gullo et al., 1999).
In addition, studies by Terbrack et al. (1996), Soldan et al. (1996), Gullo et al. (1999), Wallis et al. (1997), Walkowiak et al. (1999) and Cade et al. (2000) showed an excellent sensitivity and specificity for the diagnosis of cystic fibrosis with pancreatic involvement.

» The test
Further indications, advantages, reference concentration, specificity and sensitivity, method of detection, sample material, short protocol

» References/literature download
Please find here selected literature as download. The complete list of references is to be found on “References/literature fax request”.

» References/literature fax request
Here you can download a pdf-file with a list of references/literature. If you you are interested in any of these publications please fill in the form, fax it to us and we will send it to you free of charge.

Click here to download our flyer.

Pancreas-Quick-TMScheBo®  Pancreas Elastase 1 Quick™ Test

Stool Test for Exocrine Pancreatic Function Testing

Faecal Pancreatic Elastase 1
The Gold Standard for Non-Invasive Exocrine
Pancreatic Function Testing

… now also available as a rapid test

The ScheBo®   Pancreas Elastase 1 Quick™ stool test is a reliable and easy to perform rapid test for the detection of Pancreatic Elastase 1 in stool samples

Advantages of the ScheBo® Pancreas Elastase 1 Quick™ test:

  • A small stool sample is sufficient
  • Test results available within minutes
  • High sensitivity and specificity
  • Easy to perform
  • No additional equipment necessary
  • Pancreatic Elastase 1 is stable during intestinal transit
  • Absolutely pancreas specific
  • Uses monoclonal antibodies
  • Enzyme therapy does not affect the test result
  • Not affected by foodstuffs
  • No special diet required

Indications for use of the ScheBo®  Pancreas Elastase 1 Quick™ test:

  • Diagnosis/exclusion of pancreatic involvement in association with gastrointestinal symptoms: e.g., Maldigestion (Steatorrhoea/Diarrhoea), Abdominal Pain or ´Failure to Thrive”
  • Diagnosis/exclusion of exocrine pancreatic insufficiency in: e.g., chronic Pancreatitis, Cystic Fibrosis, Diabetes, Coeliac Disease, Irritable Bowel Syndrome (IBS), Infl ammatory Bowel Diseases (IBD), Cholelithiasis (Gallstones), Osteoporosis or Papillary Stenosis

Please check with ScheBo Biotech if this product is available in your country.

Click here to download our flyer.